AIM
FPRX

ARK Investment Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

ARK Investment Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-183,094
Closed -$2.9M – 209
2018
Q2 		$2.9M Buy
183,094
+114,240
+166% +$1.99M 0.11% 77
2018
Q1 		$1.18M Buy
68,854
+25,639
+59% +$500K 0.06% 98
2017
Q4 		$947K Buy
43,215
+21,211
+96% +$682K 0.08% 101
2017
Q3 		$900K Buy
22,004
+7,830
+55% +$246K 0.11% 92
2017
Q2 		$427K Buy
14,174
+10,623
+299% +$332K 0.08% 85
2017
Q1 		$128K Buy
3,551
+351
+11% +$15.5K 0.04% 90
2016
Q4 		$160K Buy
+3,200
New +$168K 0.06% 84

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ARK Investment Management's FPRX Position: Q3 2018 in Review

ARK Investment Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2018, closing a stake of 183,094 shares — an estimated $2.9M sold.

ARK Investment Management first reported a position in FPRX in Q4 2016 and held it in 7 quarters. The position peaked at $2.9M in Q2 2018. 114 funds tracked by Wall St. Rank hold FPRX as of Q3 2018.

  • ARK Investment Management reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • ARK Investment Management sold 183,094 Five Prime Therapeutics, Inc. shares in Q3 2018, an estimated $2.9M.
  • ARK Investment Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2016 and held it in 7 quarters.
  • ARK Investment Management's Five Prime Therapeutics, Inc. position peaked at $2.9M in Q2 2018.
  • 114 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2018.

Based on ARK Investment Management's 13F filing for Q3 2018, filed 7 Nov 2018.